Key TakeawaysA $400 million, four-year Blackstone Life Sciences financing supports ongoing and future duvakitug development, with consideration including an FDA-approval milestone, additional commercial milestones, and low single-digit global royalties.Duvakitug targets TL1A, positioning the asset to address both inflammatory activity and fibrosis biology implicated in stricturing disease and obstruction risk in ulcerative colitis and Crohn’s disease.The […]
